Donafenib after surgery for high-risk liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove liver cancer about 4 weeks ago
- Your cancer is at high risk of coming back after surgery
- You have not had any other cancer treatments before surgery, except for TACE, traditional Chinese medicine, or interferon
- Your liver is working well (Child-Pugh class A)
- You are able to do your daily activities without help (ECOG 0 or 1)
- A CT or MRI scan after surgery shows no signs of cancer left behind
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two drugs (donafenib and sintilimab) plus a liver-directed chemotherapy infusion (HAIC) before surgery for liver cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) for people with advanced liver cancer that got worse after initial treatment with immunotherapy. The goal is to see if this 'rechallenge' approach can help control the cancer again.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.